Mitomycin-C And Vp16 In Advanced Breast-Cancer - A Phase-Ii Study

A combination of VP16 (100 mg/m2 iv, days 1,2,3) and Mitomycin C (10 mg/m2 i.v. day 1), cycle repeated every 28 days, was administered to 22 previously treated patients with advanced breast cancer. Of the 22 evaluable patients 9 (41%) responded with 4 (18%) complete remissions. Median time to treatment failure was 5 months (range 4-23). Response rates were regardless of previous chemotherapy. Responses also occurred in patients pretreated with doxorubicin-containing regimens. The side effects included nausea and vomiting, slight myelosuppression and alopecia: all of them were mild and a delayed treatment instead of a dose reduction was performed. The combination of VP16 and Mitomycin C is an active and well tolerated regimen for metastatic breast cancer.